IDH1 Inhibitor 7-d2

• CAT Number: S000206
• CAS Number: 2135309-51-0
• Molecular Formula: C22H22D2F3N7O
• Molecular Weight: 461.48
• Purity: ≥95%
• Target: Isocitrate Dehydrogenase (IDH)
• IUPAC Name: (5S)-4,4-dideuterio-5-propan-2-yl-1-[2-[[(1S)-1-[1-[4-(trifluoromethyl)phenyl]imidazol-4-yl]ethyl]amino]pyrimidin-4-yl]imidazolidin-2-one
• InChI: InChI=1S/C22H24F3N7O/c1-13(2)18-10-27-21(33)32(18)19-8-9-26-20(30-19)29-14(3)17-11-31(12-28-17)16-6-4-15(5-7-16)22(23,24)25/h4-9,11-14,18H,10H2,1-3H3,(H,27,33)(H,26,29,30)/t14-,18+/m0/s1/i10D2
• InChIKey: LVRDYDOHWFEBQG-RDMILJEOSA-N
• SMILES: [2H]C1([C@@H](N(C(=O)N1)C2=NC(=NC=C2)N[C@@H](C)C3=CN(C=N3)C4=CC=C(C=C4)C(F)(F)F)C(C)C)[2H]

IDH1 Inhibitor 7-d2 (CAS: 2135309-51-0), a premium pharmaceutical research compound designed for advanced oncology and metabolic studies. As a deuterated analog of IDH1 Inhibitor 7, it offers enhanced stability and improved pharmacokinetic properties. IDH1 Inhibitor 7-d2 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies targeting IDH1 mutations in cancer. Trusted by leading laboratories, IDH1 Inhibitor 7-d2 is your go-to solution for cutting-edge cancer research. Unlock new possibilities in oncology treatment with IDH1 Inhibitor 7-d2, where innovation meets reliability.

Reference

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[Content Brief]

[2]. Lei Jang, et al. Compound having mutant idh inhibitory activity, preparation method and use thereof. Patent WO2017162133A1.